MCID: CYT004
MIFTS: 35

Cytomegalic Inclusion Disease

Categories: Rare diseases

Aliases & Classifications for Cytomegalic Inclusion Disease

MalaCards integrated aliases for Cytomegalic Inclusion Disease:

Name: Cytomegalic Inclusion Disease 49
Cytomegalic Inclusion Body Disease 49 50 69
Giant Cell Inclusion Disease 49 50
Cytomegalovirus Infections 69
Cibd 49

Classifications:



External Ids:

Summaries for Cytomegalic Inclusion Disease

NINDS : 50 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.  

MalaCards based summary : Cytomegalic Inclusion Disease, also known as cytomegalic inclusion body disease, is related to pneumonia and leukemia, and has symptoms including pruritus and fever. The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, t cells and eye.

Wikipedia : 72 Cytomegalic inclusion body disease (CIBD) is a series of signs and symptoms caused by cytomegalovirus... more...

Related Diseases for Cytomegalic Inclusion Disease

Graphical network of the top 20 diseases related to Cytomegalic Inclusion Disease:



Diseases related to Cytomegalic Inclusion Disease

Symptoms & Phenotypes for Cytomegalic Inclusion Disease

UMLS symptoms related to Cytomegalic Inclusion Disease:


pruritus, fever

Drugs & Therapeutics for Cytomegalic Inclusion Disease

Drugs for Cytomegalic Inclusion Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
2
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
4
Cidofovir Approved Phase 4,Phase 3,Phase 2,Phase 1 113852-37-2 60613
5
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
8
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
9
Foscarnet Approved Phase 4,Phase 3,Phase 2,Phase 1 4428-95-9, 63585-09-1 3415
10
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
12
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
13
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
14
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 175865-60-8 64147
15
Probenecid Approved, Investigational Phase 4,Phase 2,Phase 1 57-66-9 4911
16
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
17
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 657311 5754
18
Infliximab Approved Phase 4 170277-31-3
19
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
20
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
21
Pancrelipase Approved, Investigational Phase 4 53608-75-6
22
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
23
Azathioprine Approved Phase 4 446-86-6 2265
24 tannic acid Approved, Nutraceutical Phase 4
25
Phosphonoacetic Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 4408-78-0 546
26 triamcinolone acetonide Phase 4
27 Prednisolone acetate Phase 4,Phase 3
28 glucocorticoids Phase 4,Phase 3
29 Methylprednisolone acetate Phase 4,Phase 3
30 Methylprednisolone Hemisuccinate Phase 4,Phase 3
31 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
32 Ganciclovir triphosphate Phase 4,Phase 3,Phase 2,Phase 1
33 Gastrointestinal Agents Phase 4,Phase 1
34 Neuroprotective Agents Phase 4
35 Triamcinolone diacetate Phase 4
36 Triamcinolone hexacetonide Phase 4
37 Cyclosporins Phase 4,Phase 3
38 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
39 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40 Hormone Antagonists Phase 4,Phase 3,Phase 2
41 Hormones Phase 4,Phase 3,Phase 2
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
44 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
45 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
46 Antiemetics Phase 4
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Antifungal Agents Phase 4,Phase 3,Phase 2
49 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
50 Antilymphocyte Serum Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 338)

# Name Status NCT ID Phase Drugs
1 Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
2 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
3 Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients Unknown status NCT00364052 Phase 4 oral Valganciclovir vs oral Ganciclovir
4 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
5 Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
6 The Influence of Chronic CMV Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
7 Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant Recipients Completed NCT00436384 Phase 4
8 Influence of Persistent CMV-infection on Immune Senescence Completed NCT00461695 Phase 4
9 Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
10 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
11 Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients Completed NCT00373165 Phase 4 Ganciclovir
12 Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
13 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
14 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
15 VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
16 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
17 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
18 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
19 Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
20 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
21 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
22 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
23 Everolimus in de Novo Heart Transplant Recipients Completed NCT01017029 Phase 4 Everolimus;Mycophenolate mofetil + Everolimus
24 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir Completed NCT01651585 Phase 4 Valacyclovir arrow
25 Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen Completed NCT00170820 Phase 4 Everolimus
26 Individually Adapted Immunosuppression in de Novo Renal Transplantation Based on Immune Function Monitoring: a Prospective Randomised Study Completed NCT00895206 Phase 4 individual adapted immunosuppression;golden standard therapy
27 Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
28 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
29 CMV-CTL for the Treatment of CMV Infection After HSCT Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
30 Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
31 PTH - Preemptive Treatment for Herpesviridae Recruiting NCT02152358 Phase 4 Aciclovir;Ganciclovir;Placebo
32 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Active, not recruiting NCT02328963 Phase 4 Everolimus;mycophenolic acid
33 Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant Active, not recruiting NCT02550639 Phase 4
34 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients Active, not recruiting NCT01552369 Phase 4 Prophylaxis with Valganciclovir
35 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
36 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
37 Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
38 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Unknown status NCT02005822 Phase 3 Valganciclovir
39 Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor Unknown status NCT00733733 Phase 3 ATG Fresenius
40 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3 Valganciclovir
41 Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
42 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections Completed NCT00466817 Phase 3 Valganciclovir
43 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
44 Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
45 Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
46 Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Completed NCT02137772 Phase 3 Letermovir;Placebo
47 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients Completed NCT00497796 Phase 3 maribavir;ganciclovir
48 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients Completed NCT00411645 Phase 3 maribavir
49 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation Completed NCT00372229 Phase 3 Pre-emptive therapy;valganciclovir [Valcyte]
50 The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection. Completed NCT00275665 Phase 3 Valganciclovir

Search NIH Clinical Center for Cytomegalic Inclusion Disease

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Cytomegalic Inclusion Disease

Anatomical Context for Cytomegalic Inclusion Disease

MalaCards organs/tissues related to Cytomegalic Inclusion Disease:

38
Kidney, T Cells, Eye, Liver, Bone, Testes, Bone Marrow

Publications for Cytomegalic Inclusion Disease

Articles related to Cytomegalic Inclusion Disease:

(show top 50) (show all 197)
# Title Authors Year
1
Cytomegalic Inclusion Disease caused by Cytomegalovirus Infection in the Salivary Glands ofA an African Hedgehog (Atelerix arbiventris). ( 29169627 )
2017
2
Severe fetal cytomegalic inclusion disease after documented maternal reactivation of cytomegalovirus infection during pregnancy. ( 10740207 )
2000
3
A fatal case of congenital cytomegalic inclusion disease following recurrent maternal infection. ( 8590396 )
1995
4
Temporal bone histopathology 14 years after cytomegalic inclusion disease: a case study. ( 8395628 )
1993
5
Disseminated cutaneous cytomegalic inclusion disease resembling prurigo nodularis in a HIV-infected patient: a case report and literature review. ( 7964230 )
1993
6
Cytomegalic inclusion disease presenting acute intrahepatic cholestasis. ( 1338619 )
1992
7
Salivary gland oncocytes in African hedgehogs (Atelerix albiventris) mimicking cytomegalic inclusion disease. ( 1655834 )
1991
8
Cytomegalic inclusion disease: intrauterine sonographic diagnosis using findings involving the brain. ( 1846993 )
1991
9
Successful treatment of disseminated cutaneous cytomegalic inclusion disease associated with Hodgkin's disease. ( 1847957 )
1991
10
A viral infection causing cytomegalic inclusion disease in the renal epithelium of the platypus (Ornithorhynchus anatinus). ( 2154629 )
1990
11
Spontaneous disseminated cytomegalic inclusion disease in an ageing laboratory mouse. ( 2843585 )
1988
12
Evaluation of diagnostic criteria for mucosal cytomegalic inclusion disease in the acquired immune deficiency syndrome. ( 2825515 )
1987
13
Glomerulonephritis in congenital cytomegalic inclusion disease. ( 3019866 )
1986
14
Reactivation of congenital cytomegalic inclusion disease in an infant with HTLV-III associated immunodeficiency: a CT-pathologic correlation. ( 3009568 )
1986
15
The incidence of cytomegalic inclusion disease (CID) in an obstetric teaching hospital, 1975-1984. ( 3002314 )
1985
16
Disseminated intravascular coagulation induced by generalized cytomegalic inclusion disease during steroid therapy for polymyositis. ( 2994360 )
1985
17
Cytomegalic inclusion disease after recurrent maternal infection. ( 2865630 )
1985
18
Sudden infant death with congenital cytomegalic inclusion disease. ( 6324573 )
1984
19
Neonatal cytomegalic inclusion disease in a set of twins one member of whom was a hydropic stillbirth the other completely uninfected. Case report. ( 6299328 )
1983
20
Two-dimensional ultrasonography of the brain: its diagnostic usefullness in herpes simplex encephalitis and cytomegalic inclusion disease. ( 6311039 )
1983
21
Computed tomography in the diagnosis of congenital cytomegalic inclusion disease. ( 6293102 )
1982
22
Cytomegalic inclusion disease diagnosed endoscopically. ( 6257456 )
1981
23
Cytomegalic inclusion disease of the skin. ( 6261699 )
1981
24
Adult pulmonary cytomegalic inclusion disease: report of a case. ( 6244337 )
1980
25
Adult cytomegalic inclusion disease. ( 6259726 )
1980
26
Generalized cytomegalic inclusion disease in neonates and infants. ( 6249068 )
1980
27
Adult T-cell leukemia with generalized cytomegalic inclusion disease and pneumocystis carinii pneumonia. ( 233285 )
1979
28
Osseous lesions and pathologic fractures in congenital cytomegalic inclusion disease: report of a case. ( 231493 )
1979
29
Cytomegalic inclusion disease: a study of fifty-five autopsies. ( 226645 )
1979
30
Noncirrhotic portal fibrosis following neonatal cytomegalic inclusion disease. ( 213550 )
1978
31
Hepatic calcification in congenital cytomegalic inclusion disease. ( 205645 )
1978
32
Ocular cytomegalic inclusion disease in the adult. ( 214905 )
1977
33
The otologic manifestations of cytomegalic inclusion disease - a case report. ( 193219 )
1977
34
Fatal cytomegalic inclusion disease. Associated skin manifestations in a renal transplant patient. ( 201217 )
1977
35
Calcification in liver associated with congenital cytomegalic inclusion disease. ( 190372 )
1977
36
Pseudoglioma and cytomegalic inclusion disease. ( 192400 )
1976
37
Generalized porcine cytomegalic inclusion disease: distribution of cytomegalic cells and virus. ( 178692 )
1976
38
Disseminated cytomegalic inclusion disease in an adult with cirrhosis of liver and review of literatures. ( 190080 )
1976
39
Cytomegalic inclusion disease in the east African headgehog. ( 167206 )
1975
40
Bone changes in congenital cytomegalic inclusion disease. ( 165786 )
1975
41
Cytomegalic inclusion disease with petechiae and thrombocytopenia at birth. ( 166764 )
1975
42
An autopsy case of generalized cytomegalic inclusion disease associated with Pneumocystis carinii pneumonia. ( 173920 )
1975
43
An autopsy case of isolated myocarditis probably associated with infectious mononucleosis and disseminated cytomegalic inclusion disease. ( 4365594 )
1974
44
Massive fetal ascites, urethral atresia, and cytomegalic inclusion disease. ( 4365977 )
1974
45
Fecal excretion of cytomegalovirus in disseminated cytomegalic inclusion disease. ( 4365949 )
1974
46
Unusual glomerular change in cytomegalic inclusion disease. ( 4374799 )
1974
47
A sensitive cell culture system for the virus of porcine inclusion body rhinitis (cytomegalic inclusion disease). ( 4350592 )
1973
48
Cytomegalic inclusion disease treated with idoxuridine and novobiocin. ( 4118557 )
1973
49
Letter: Bilateral eventration of the diaphragm in a neonate with congenital cytomegalic inclusion disease. ( 4358655 )
1973
50
Monoclonal macroglobulinemia and cytomegalic inclusion disease. ( 4350589 )
1973

Variations for Cytomegalic Inclusion Disease

Expression for Cytomegalic Inclusion Disease

Search GEO for disease gene expression data for Cytomegalic Inclusion Disease.

Pathways for Cytomegalic Inclusion Disease

GO Terms for Cytomegalic Inclusion Disease

Sources for Cytomegalic Inclusion Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....